ogsiveo

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…

2 months ago